The cardiovascular protection offered by GLP-1 receptor agonists stems from several complementary mechanisms: Anti-inflammatory effects through suppression of CRP, TNF-, and other inflammatory markers Substantial weight reduction, particularly with higher doses of newer agents Blood pressure modulation via direct vascular effects and enhanced natriuresis Improved endothelial function and lipid profiles Renal protective effects, including reduced albuminuria and slowed eGFR decline Though initially established in type 2 diabetes populations, recent evidence from the SELECT trial confirms these benefits extend to non-diabetic patients with obesity and established cardiovascular disease
Our options include the injectable Wegovy, designed for once-weekly administration with a pre-filled pen
Ozempic received FDA approval in 2017 specifically for improving blood sugar control in adults with Type 2 diabetes
Do you offer other weight loss injections
This safety profile makes them a preferred option for men who need to control their blood sugar levels without the constant worry of dropping too low
Because it will operate outside the Part D benefit, the $50 copayment wont count towards the Part D deductible or the $2,100 out-of-pocket spending cap
